Dizal (Jiangsu) Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Zhang Xiaolin
Chief executive officer
CN¥9.5m
Total compensation
CEO salary percentage | n/a |
CEO tenure | no data |
CEO ownership | 1.8% |
Management average tenure | 1.3yrs |
Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Share Price Could Signal Some Risk
Dec 24Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?
Aug 20Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHSE:688192) Analysts Just Slashed This Year's Revenue Estimates By 12%
May 02Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?
Apr 30CEO
Zhang Xiaolin (60 yo)
no data
Tenure
CN¥9,534,800
Compensation
Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
GM & Chairman | no data | CN¥9.53m | 1.76% CN¥ 312.2m | |
CFO & Board Secretary | 4.9yrs | CN¥4.07m | no data | |
Deputy GM | 1.3yrs | CN¥1.81m | 0.024% CN¥ 4.3m | |
Deputy GM | no data | CN¥2.03m | 0.072% CN¥ 12.8m | |
Deputy GM & Chief Medical Officer | no data | CN¥3.59m | 1.09% CN¥ 193.8m | |
Deputy GM & Chief Commercial Officer | no data | CN¥5.23m | 0.0028% CN¥ 504.1k | |
Deputy GM | 1.3yrs | CN¥2.31m | 0.072% CN¥ 12.8m | |
Deputy GM | no data | CN¥2.76m | 0.0096% CN¥ 1.7m | |
Deputy GM & Senior VP of Clinical Operations | no data | CN¥2.98m | 0.11% CN¥ 19.6m | |
VP & Head of Registration Affairs | 1.3yrs | CN¥1.98m | 0.048% CN¥ 8.5m | |
Vice President of Clinical Pharmacology | no data | CN¥1.72m | 0.0072% CN¥ 1.3m | |
Employee Supervisor & Head of Accounting Agency | no data | no data | 0.0041% CN¥ 725.9k |
1.3yrs
Average Tenure
56yo
Average Age
Experienced Management: 688192's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
GM & Chairman | no data | CN¥9.53m | 1.76% CN¥ 312.2m | |
Employee Supervisor & Head of Accounting Agency | 2.8yrs | no data | 0.0041% CN¥ 725.9k | |
Independent Director | 4.3yrs | CN¥100.00k | no data | |
Director | 7.9yrs | no data | no data | |
Director | 7.9yrs | no data | no data | |
Independent Director | 4.3yrs | CN¥100.00k | no data | |
Independent Director | 4.3yrs | CN¥100.00k | no data | |
Independent Director | 4.3yrs | CN¥100.00k | no data | |
Chairman of the Supervisory Board | no data | no data | no data | |
Supervisor | no data | no data | no data |
4.3yrs
Average Tenure
52yo
Average Age
Experienced Board: 688192's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 16:24 |
End of Day Share Price | 2024/12/25 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dizal (Jiangsu) Pharmaceutical Co., Ltd. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Pei Cheng | China Galaxy Securities Co., Ltd. |
Ziyu He | China International Capital Corporation Limited |
Jin Zhang | China International Capital Corporation Limited |